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N-linked glycosylationRecent discovery of several potent and broadly neutralizing monoclonal antibodies (MAbs) (such as PG9 and
PG16) to HIV-1 provided clues on newer vaccine targets. In the present study, we found an env clone
obtained from a slow progressor showing signiﬁcant resistance to PG9 and PG16 MAbs in sharp contrast to
other contemporaneous autologous env clones. By constructing chimeric envelopes and speciﬁc substitutions
we found that both loop length and spatial orientation of glycan residues in addition to the net charge of the
β sheet C region that directly binds to PG9 CDRH3 within V2 loop signiﬁcantly modulated HIV-1 sensitivity to
PG9 and PG16 MAbs. Similar observation were made with several other Envs which varied in length, glycan
content and net charge in PG9 contacting complementary region in V2 loop. Our data indicated that subtle
change within V2 loop alone modulates exposition of quaternary epitopes that are targets of PG9/PG16 MAbs.
© 2012 Elsevier Inc. All rights reserved.Introduction
It is widely believed that a successful protective vaccine to Human
Immunodeﬁciency virus type-1 (HIV-1) needs to elicit neutralizing
antibodies that would be broad and ideally very potent. Very recently,
broadly neutralizing monoclonal antibodies (MAbs) to HIV-1 have
been discovered that were found to be very potent in nature and
which targets quaternary epitopes (QNE) (such as PG9, PG16 and
PGT antibodies) (Walker et al., 2009, 2011) in variable loops and
CD4 binding sites (CD4bs) (such as VRC01) (Wu et al., 2010; Zhou
et al., 2010). More recently, Pejchal et al. (Pejchal et al., 2011) showed
the mechanism by which the few potent MAbs such as PGT 127 and
PGT 128 overcome the glycan shield towards comprehensive neutral-
ization. The HIV-1 envelope glycoprotein (Env) is a major target of
the neutralizing antibodies wherein HIV-1 Env develops cascade of
mechanism towards humoral immune evasion by conferring inacces-
sibility of important/key residues on Env trimers that acts as targets
of neutralizing antibodies. Several mechanisms attributed to this phe-
nomenon have been documented; however (1) the number of poten-
tial glycosylation sites (PNGS) and (2) the length of variable loopsVirology,
une-411027,
tacharya).
wiftwater, PA, USA.
rights reserved.especially in the context of V1V2 and V3 associated with neutraliza-
tion sensitivity/resistance of HIV-1 were extensively reported
(Bunnik et al., 2008; Cao et al., 1997; Chackerian et al., 1997; Chen
et al., 2005; Decker et al., 2005; Doores and Burton, 2010; Doores et
al., 2010; Edwards et al., 2001; Fischer et al., 1995; Go et al., 2008;
Kwong et al., 1998; Land et al., 2003; Mascola and Monteﬁori, 2010;
Moore et al., 2009; Pantophlet and Burton, 2006; Rong et al., 2007;
Sagar et al., 2006; van Gils et al., 2010, 2011; Wei et al., 2003;
Wyatt et al., 1995). It was previously shown that alteration in PNGS
in V1, V2 and V3 signiﬁcantly modulated sensitivity of Env-
pseudotyped HIV-1 to PG9 and PG16 MAbs (Doores and Burton,
2010). PNGS at position 156 in V1 and 160 in V2 loops were shown
to be the indispensable components of PG9 and PG16 MAb epitopes
and alanine substitution at these sites were found to signiﬁcantly
abolish the binding and neutralization sensitivity of HIV-1 Envs to
PG9 and PG16 MAbs. Previously, the following residues: S158, F159,
T162, Y173 and F176 in V2 loop were shown to profoundly alter the
PG9 and PG16 MAb sensitivity (Walker et al., 2009). Very recently,
McLellan et al. (McLellan et al., 2011) through high resolution crystal
structure have narrowed down the PG9 contacting sites in the V2
loop and showed that the much of the binding area covers the sugars
of glycan at 156 and 160 position and strand of the CDRH3 of PG9
forms intermolecular parallel β-sheet-like hydrogen bonds to strand
C of V2. In the present study, we sought to investigate the basis of nat-
ural resistance of a patient Env obtained from plasma of a slow pro-
gressing Indian patient to PG9/PG16 MAbs in sharp contrast to its
Table 1
Effect of V2 mutations on neutralization sensitivity of LT5 envelopes to PG9 and PG16
monoclonal antibodies.
Envelopes Neutralization titers
(IC50)
Fold IC50 decrease
relative to LT5.J3b
PG9 PG16 PG9 PG16
LT5.J3b 1.5 1.75 – –
LT5.J4b 0.006 0.0009 250 1944
LT5.J7b 0.090 0.025 16.60 70
LT5.J12 0.080 0.065 18.75 27
N188PNG >1 0.5 >1 3.5
N190A 0.126 0.015 12 116.6
ΔN188ΔS189 0.130 0.032 11.53 54.68
35R. Ringe et al. / Virology 426 (2012) 34–41contemporaneous autologous Envs. We found that subtle alterations
in length and PNGS in V2 loop of gp120 globally modulated PG9/
PG16 sensitivity.Results and discussion
Patient-derived Env clones varied in their sensitivity to PG9 and PG16
MAbs
Several complete Env genes (gp160) were ampliﬁed from plasma
of a slow progressing Indian patient (991566) with broad serum neu-
tralizing antibody as recently described (Mukhopadhyay et al., 2011),
of which four gp160 clones (LT5.J4b, LT5.J3b, LT5.J7b and LT5.J12)
showed functionality when tested as Env-pseudotyped viruses in
TZM-bl cells (Table 1). On further analysis, one of the Env clones
(LT5.J4b) showed exceptional sensitivity to autologous serum antibody
and was further found to expose neutralizing epitopes at different sites
in the Env (Ringe R and Bhattacharya, J. Manuscript under preparation).
However, when tested against PG9 and PG16 MAbs, all except one Env
clone (LT5.J3b) showed comparable sensitivity to both PG9 and PG16
MAbs at a very lowdose (Fig. 1A). As shown in Fig. 1A, amongst the con-
temporaneous Envs, LT5.J3b showed considerable resistance to both
PG9 and PG16 MAbs (the neutralization titer (IC80) of LT5.J4b, LT5.J7b
and LT5.J12 was found to be >700 fold; 25.6 and >100 fold; and 95
and>400 fold less compared to LT5.J3b against PG9 and PG16MAbs re-
spectively). This striking difference in PG9/PG16 sensitivity prompted%
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Fig. 1. Neutralization of pseudotyped viruses expressing wild type patient Envs (A) and chim
% neutralization shown on Y-axis. C. V1V2 loop sequence alignment of amino acids of wild ty
are represented by ‘dots’.us to further investigate the basis underlying this neutralization
phenotype.
Subtle change in PNGS and length of V2 modulated PG9/PG16 sensitivity
Based on previous studies (Doores and Burton, 2010;Walker et al.,
2009) which revealed the presence of quaternary epitopes targeted
by PG9/PG16 MAbs in variable loops in gp120, we ﬁrst sought to
ﬁnd out if alteration within V1V2 loop played any role in modulation
of PG9/PG16 sensitivity. Since, pseudotyped viruses expressing
LT5.J4b Env showed maximal inhibition by PG9 and PG16 MAbs; in
order to ﬁnd the basis of resistance of LT5.J3b Env to PG9/PG16
MAbs, we constructed chimeric Envs by replacing V1V2, C2V3 and
C3V4 regions from LT5.J3b with that of LT5.J4b. Pseudotyped viruses
expressing chimeric Envs were then assessed for their sensitivities
to PG9/PG16 MAbs in neutralization assay in TZM-bl cells. As shown
in Fig. 1B, LT5.J3b Env expressing J4b V1V2 (LT5.J3b/J4bV1V2) was
found to show comparable sensitivity to PG9/PG16 MAbs as LT5.J4b
wild type Env, suggesting that V1V2 sequence of LT5.J3b was respon-
sible for conferring PG9/PG16 resistance.
As PG9 and PG16 recognize the conformational epitopes and that it
is inﬂuenced by the N-linked glycosylation pattern in variable loops
(Doores and Burton, 2010) we examined the glycosylation proﬁle of
V1V2 of all four Envs. In the V1 region, LT5.J4b and LT5.J7b contained
four PNGswhereas LT5.J3b and LT5.J12 contained ﬁve PNGs respective-
ly. Considering the neutralization sensitivity of these Envs to PG9 and
PG16 the glycan proﬁle in V1 region indicated that the number of
PNGs in this region may not play a role in modulating the sensitivity
to PG9/PG16 MAbs. Recently, McLellan et al. (McLellan et al., 2011)
have shown that the PG9 makes avid contact with β strand C domain
in V2 loop apart from glycan at 160 through its long CDRH3 loop. Com-
parison of V1V2 sequence of Envs which are potently neutralized by
PG9 MAb showed that sequence of V2 is more conserved whereas V1
sequence is highly varied indicating that the binding or interaction of
PG9 was not much dependent on V1 loop and therefore we have fo-
cused on the possible role of V2 loop in modulating neutralization sen-
sitivity in LT5 Envs. We examined the number of PNGs in V2 region
which revealed LT5.J3b, LT5.J7b and LT5.J12 each contained three
PNGs while LT5.J4b had only two. All four Envs had conserved N-
linked glycosylation site at 156 in V1 and 160 in V2. We further noted
that LT5.J3b had two amino acid insertions (N188/S189) proximal to[µg/ml]
J3b(J4b V1V2)/PG9
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36 R. Ringe et al. / Virology 426 (2012) 34–41the PNG N190 in the V2 region shifting the position of PNG at 190 as
compared to other Envs especially LT5.J7b and LT5.J12 both of which
were sensitive to PG9/PG16 as compared to LT5.J3b (Fig. 1).We hypoth-
esized that insertion of N188/S189 residues in LT5.J3b shifted the posi-
tion of PNG at 190 and possibly conferred resistance to PG9 and PG16.
To evaluate the position effect of this PNGweprepared the deletionmu-
tant of LT5.J3b where N188/S189 motif was removed and PNG at 190
was replaced to perfectly align with that of LT5.J7b and LT5.J12
(Fig. 1C). Neutralization data (Fig. 2B) revealed that removal of N188/
S189 conferred increased sensitivity of LT5.J3b and closely matched
with that of LT5.J7b and LT5.J12 Envs. This data suggested that presence
of PNG at the 190 position in V2 loop plays an important role in modu-
lating the neutralization sensitivity of LT5.J3b to PG9 and PG16. Next, to
dissect the role of N190, we substituted asparagine (N)with alanine (A)
at the position 190 (N190A) in LT5.J3b Env. We found that removal of
glycan site at this position (N190A) showed modest increment in the
neutralization sensitivity of LT5.J3b Env (N190A) to PG9 and PG16
MAbs and was comparable to deletion mutant LT5.J3b (ΔN188/
ΔS189). Further to evaluate the effect of the presence of additional
PNG in V2 loop on PG9/PG16 sensitivity, we converted N188 in
LT5.J3b Env into a PNG by incorporating a serine (S) residue next to
N188S189 (Fig. 2A). When tested, LT5.J3b expressing additional PNG
(N188/S189/S190) (Fig. 1C) did not show any further neutralization re-
sistance to PG9/PG16 MABs (Fig. 2A) to LT5.J3b wild type, suggesting
that PNG at 190 likely hinders the PG9/PG16 binding and affect Env
neutralization when it is properly positioned in the V2 loop. ApartB
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Fig. 2. A. V2 loop sequence alignment of amino acids of wild type and mutant LT5.J3b Envs.
S189 residues present in LT5.J3b are highlighted in wild type V2 sequence alignment. B. Ne
PG9 and PG16 MAbs at different doses. Note that N188 was made a PNG by inserting a serin
carried with Envs expressed on 293 T cells with different concentrations of PG9 and PG16 M
units (RLU).from N190, we next examined whether N194 (present within V2
loop)whichwas found to be conserved in all four LT5 Envs, works in co-
operation with N190. Thus, we made N194A substitution using LT5.J3b
Env containing N190A as a template to produce LT5.J3b (N190A/
N194A) (Fig. 2A). However, the infectivity titer of the pseudovirus
expressing this doublemutant (N190A/N194A)was found to be severe-
ly compromised and below par below to carry any neutralization assay
further. This observation indicated that N190 andN194 in V2 loop likely
play important role towards affecting arrangement within Env trimers
for attachment to cellular receptor and post-attachment phenomenon
as described earlier (Doores and Burton, 2010; Fischer et al., 1995;
Gruters et al., 1987).
Association of neutralization sensitivity with binding of PG9/PG16 MAb
with Env trimer
We further investigatedwhether therewas any association between
modulation of virus neutralization due to addition or deletion of PNGS
and changes in loop length in V2 loop with the binding of gp120 with
PG9 and PG16 MAbs closely in trimeric state. The relative interaction
of Env with PG9 and PG16 MAbs was assessed by cell-based binding
assay using 293T cells and as described in the Materials and methods.
As shown in Fig. 2B, as expected, we found a positive association be-
tween increased neutralization of Env-pseudotyped viruses with in-
creased Env binding to PG9/PG16 MAbs and vice versa. Interestingly,
the effect of N188/S189 deletion on the neutralization was more than0
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N-linked glycosylation sites are underlined in wild type and mutant Envs. Extra N188/
utralization and binding of pseudotyped viruses carrying wild type and mutant Envs to
e residue at the 190 position (N188PNG is same as S190). Cell-based binding assay was
Abs as shown in X-axis. Relative binding was assessed by measuring relative luciferase
37R. Ringe et al. / Virology 426 (2012) 34–41removal of PNG at the 190 position, whereas the inverse effect was
found in the binding assays. This might either be due to differences in
gp160 expression on viruses and transfected cells or due to the binding
differences of antibody with Env in growth medium (in neutralization
assay) and in blocking buffer (in binding assays). The discrepancy be-
tween binding and neutralization is albeit intriguing and is reported
in other studies as well ((Duenas-Decamp and Clapham, 2010; Li et
al., 2011). Our data suggested that N190 in V2 loopwas a protective gly-
can and either its absence (N190A) or subtle shift in its position due to
presence of two additional residues (N188/S189) proximal to it results
in increased binding of Env trimers to PG9/PG16 MAbs towards en-
hanced neutralization sensitivity.
Potency of HIV-1 neutralization by PG9/PG16 MAbs is dependent on
length and number of PNGS present in V2 loop
The binding and neutralization data of LT5.J3b and its mutants
revealed the role of V2 and the glycosylation sites in this loop in mod-
ulating the neutralization sensitivity to PG9 and PG16. The neutraliza-
tion sensitivity of LT5.J3b ΔN188ΔS189 mutant over wild type LT5.J3bTable 2
Neutralization sensitivity of panel of Env-pseudotyped viruses with variable lengths, glycan r
MAbs.
Envelopes Clade V1 length V2 length PNGS in V1 PNGS in V2
2-3.J17 C 25 40 3 2
2-5.J3 C 25 46 4 3
3-3.J9 C 18 41 2 3
3-5.J25 C 17 41 2 3
3-5.J38 C 21 41 2 3
4.J2 C 23 40 4 2
4.J22 C 22 40 4 2
4-2.42b C 25 40 4 2
4-2.J45b C 20 40 3 2
4-2.46b C 25 40 4 2
5.J41 C 22 51 4 5
5-3.J4 C 22 51 4 5
5-3.J9 C 22 51 4 5
7.J20 C 24 41 3 2
11.J25 C 19 46 3 2
11-5.J12 C 18 46 2 3
00836-2.5 C 22 40 3 2
26191-2.48 C 17 42 3 2
0013095-2.11 C 24 50 3 3
VB27.J2 C 26 47 4 3
VB51.J22 C 26 48 4 3
VB52.J9 C 33 42 5 2
VB95.J22 C 21 40 3 2
VB97.J5 C 29 50 5 3
VB98.J12 C 21 42 2 3
VB100.J38 C 28 43 4 3
VB100.J39 C 28 47 4 5
VB106.J38 C 21 40 4 2
LT5.J3b C 30 47 5 3
LT5.J4b B/C 26 46 4 2
LT5.J7b C 24 45 4 3
LT5.J12 B/C 30 45 5 3
6535.3 B 29 39 6 2
RHPA4259.7 B 23 46 3 3
QH0692 B 31 50 4 3
PVO.4 B 31 50 4 4
SC422661.8 B 24 47 3 3
DU156 C 25 42 3 2
DU172 C 30 46 3 3
DU422 C 27 44 3 2
ZM109 C 17 45 1 4
ZM197 C 39 49 5 3
CAP45 C 17 45 2 2
The IC50 values indicate concentrations of PG9/PG16 MAbs (μg/ml) that conferred 50% red
average of duplicate readings. All the Indian clade C envelopes were described earlier (10, 11
of V2 (residues 166–176) contacts directly with negatively charged CDRH3 region of PG9 Msuggested that the deletion of N188/S189 residues might had spatial-
ly changed the orientation of N190 resulting in less hindrance in
binding of antibody to this region (Fig. 2B). This notion was sup-
ported by the complete removal of N190 which leads to enhanced
binding of antibodies and neutralization. Importantly the most sensi-
tive Env LT5.J4b among four contained only two PNGs in V2 loop. van
Gils et al. (2011) recently described that V1V2 length and increased
glycosylation sites protect HIV-1 against neutralizing antibodies;
however did not report their consequence on PG9/PG16 MAbs.
Thus, to explore this, we tested a panel of 43 Env-pseudotyped virus-
es having differential V2 loop length and number of PNGS within this
region (Table 2). All the 43 Envs except ZM109 that we tested were
found to possess N156 (in V1 loop) and N160 (in V2 loop) glycosyla-
tion sites which were shown to be required for PG9/PG16 sensitivity
(Doores and Burton, 2010;Walker et al., 2009). This was to character-
ize the role of determinants within V2 loop on PG9/PG16 sensitivity
in presence of those essential glycans. In Env ZM109, the glycan at
the 156 position is not preserved but additional glycan at position
173 is present in the middle strand of C. This glycan is virtually pre-
sent in the same spatial location as glycan at the 156 position in Envesidues and net positive charge in β sheet C region of the V2 loop against PG9 and PG16
β sheet C region sequence
(166–176)
Net positive charge
(166–176)
IC50 (PG9) IC50 (PG16)
RDRKQKVYALF 3 0.04 b0.0078
RDRKQKVYALF 3 0.25 0.043
RDKKQTEHALF 1 >1 >1
RDKKQTVHALF 2 >1 >1
RDKKQTVHALF 2 >1 >1
RDRKQRVQALF 3 b0.0078 b0.0078
RDRKRRVQALF 4 b0.0078 b0.0078
RDRKQRVQALF 3 0.017 0.015
RDRKQRVQALF 3 0.018 0.045
RDRKQRVQALF 3 0.06 0.018
KNRKKKEYALF 4 0.25 0.584
KDRKKKEYALF 3 >1 >1
KDRKKKEYALF 3 >1 >1
KDRKQKVYALF 3 0.05 0.0078
RDKKDTVYALF 1 0.05 0.01
RDKKDTVYALF 1 0.11 0.07
KDKKQSVYALF 2 >1 >1
RDKKKTVYSLF 3 0.134 0.721
KDKKQKVHALF 3 0.032 b0.0078
RDRKKSVYALF 3 >1 >1
KDKTQKVTALF 2 >1 >1
RDRKQKVYALF 3 0.23 0.035
RDRKQGVYALF 2 >1 >1
TDRKQEVHALF 0 >1 >1
RDKKQGVYALF 2 >1 0.389
RDKKKSVYALF 3 >1 >1
RDKKKSVYALF 3 >1 >1
RDKQQKVYALF 2 >1 0.502
KDRKRNEYALF 2 >1 >1
KDRKRNVYALF 3 b0.0078 b0.0039
KDRKRNEYALF 2 0.0625 0.0156
KDRKRNEYALF 2 0.125 0.0312
GDKRQKEYALL 1 0.172 >1
RDKVQKEYALL 1 0.12 >1
KDKVQNVYALF 1 >1 >1
RDRMQKVYALF 2 >1 >1
RDKVQKTYALF 2 0.79 >1
RDKKQKVYALF 3 0.119 b0.0078
TDKKKKEYALF 2 >1 0.574
RDKKQKVYALF 3 0.504 0.487
KDRKQKVNATF 3 0.285 >1
RDRKTKQRALF 4 0.264 0.069
RDKKQKAYALF 3 0.007 b0.0078
uction in infectivity of Env-pseudotyped viruses in TZM-bl cells. Each IC50 value is the
, 14, and 23). The GenBank accession number of 7.J20 is EU908223. The β sheet C region
Ab containing sulfated tyrosine residues (McLellan et al., 2011).
38 R. Ringe et al. / Virology 426 (2012) 34–41CAP45 and both were found to be potently neutralized by PG9/16
monoclonal antibodies. Therefore, the glycan status of ZM109 is
much similar to other Envs in the panel as far as binding elements
of PG9/16 on Env are concerned. As shown in Fig. 3, signiﬁcant corre-
lations between shorter V2 length and less PNGS in V2 loop with in-
creased Env susceptibility to PG9 and PG16 MAbs were found.
Interestingly, in regards to PNGS, we found signiﬁcant differences in
virus neutralization to by PG9 and PG16 MAbs even with one change
in PNG. Thus, as shown in Figs. 3 and 4A, we found that presence of
two PNGs in V2 loop of Env-pseudotyped viruses showed signiﬁcant
PG9 and PG16 sensitivity over those which contained three or more
PNGS. It was noted that this effect was much more profound with
PG16 MAb. Our data clearly suggested that V2 loop length and num-
ber of PNGS present within governs the degree of HIV-1 susceptibility
to PG9/PG16 MAbs. However, such association was not found with V1
alone or V1V2 as a whole (Fig. 3). Our data thus suggested that the
determinants of PG9 and PG16 sensitivity were more concentrated
in V2 rather than V1. The probable reason of correlation of length of
V2 loop with the sensitivity might be that more PNGs are accommo-
dated with acquisition of length. We have observed a positive corre-
lation of V1V2 length with the number of PNGs in this region (data
not shown). In order to evade the neutralizing antibodies the glycans
and length are co-acquired in the HIV infection which modulates the
neutralization sensitivity to these newly discovered antibodies PG9/
16 as well (Bunnik et al., 2008; Rong et al., 2007; van Gils et al., 2011).PG9 PG16
Number of PNGS
P=0.8011; r=-0.04059 P= 0.8756; r=-0.02522
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Fig. 3. Correlation between PNGS number and loop length in V1, V2 and V1V2 loops in gp1
MAbs. Neutralization of viruses were carried out with two fold serial diluted PG9 or PG16
0.0078 in all correlation analyses. The correlations were evaluated for statistical signiﬁcance
shown at the top of each box were obtained by using Graph Pad prism software.Potency of HIV-1 neutralization by PG9/PG16 is dependent on net
positive charge of β-strand C in V2 loop
The mutagenesis studies in LT5.J3b and the neutralization sensi-
tivity of Envs in the panel has revealed that glycans in V2 loop play
role in modulating neutralization sensitivity. Also the length of V2
loop but not V1 inﬂuences the neutralization albeit weak correlation
was observed between V2 loop length and neutralization sensitivity.
We observed that restoring the length and glycan number in V2 of
LT5.J3b has restored the sensitivity of LT5.J3b and approximately
matched that of LT5.J7b and LT5.J12 but not that of LT5.J4b.
McLellan et al. (2011) recently showed that a strand in the CDRH3
of PG9 forms intermolecular parallel β-sheet-like hydrogen bonds to
strand C of V2 loop. In addition, the positively charged residues in C
strand interact with negatively charged residues of PG9 mainly due
to the presence of sulfated tyrosines in the CDR H3 loop of antibody.
This electrostatic interaction might play an important role in modu-
lating overall neutralization sensitivity to PG9 and PG16 especially
when the important glycans at position 156 and 160 are conserved.
We next examined whether the net positive charge especially con-
tributed by the residues like lysine (K) and arginine (R) has any cor-
relation with PG9/16 sensitivity. We compared the sequence of β-
sheet C in V2 and calculated the net positive charge from 11 amino
acid sequences (166 to176)(Table 2). We found that the net positive
charge is positively correlated with the sensitivity of PG9/PG16V1V2 V1V2
PG9 PG16
P= 0.054; r=-0.2967 
P= 0.2075; r= -0.20
P= 0.6113; r= -0.82
P= 0.0469; r= -0.31
P= 0.4507; r= 0.1211
P= 0.9950; r= 0.001016
V1 V1
V2 V2
Variable loop length
20 with neutralization sensitivity (IC50) of Env-pseudotyped viruses to PG9 and PG16
starting from 1 μg/ml to 0.0078 μg/ml. IC50>1 and b0.0078 was considered as 1 and
by Spearman test. Correlation co-efﬁcient expressed as Spearman's rho (r) and P values
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Fig. 4. Correlation between (A) number of PNGS and (B) net positive charge in the β sheet C region in V2 loop on neutralization sensitivity (IC50) of Env-pseudotyped viruses to PG9
and PG16 MAbs. A total of 43 Envs from different genetic backgrounds were divided into groups on the basis of number of PNGSs in V2 (2, 3 and >3) as well as net charge in the β
sheet C region in V2 loop (≤2 and ≥3). The median neutralization sensitivity of Envs to PG9 and PG16 MAbs is shown by horizontal line and P value between two columns was
calculated by using Wilcoxon signed rank test and were obtained between different groups.
39R. Ringe et al. / Virology 426 (2012) 34–41(Fig. 4B). The median IC50 of the Envs showing net positive charge 2
or less was found to be >1 (for both PG9 and PG16) and for the Envs
showing charge 3 or more was found to be 0.134 for PG9 and 0.043
for PG16. This data suggested that the presence of positively charged
residues possibly enhances the interaction of V2 loop with PG9/16
and contributes to increased neutralization sensitivity along with
other determinants in V2 loop. Although the deletion of NS or the re-
moval of glycan at 190 in LT5.J3b has restored the sensitivity to that of
LT5.J7b or LT5.J12 it doesn't match LT5.J4b. The highly potent neutral-
ization of LT5.J4b amongst LT5 Envs might probably be because of the
presence of two extra K in V2 loop. These two lysine residues may im-
part extra positive charge and enhance electrostatic interaction with
antibodies.
In conclusion, we demonstrate that the increased length and num-
ber of glycosylation sites in V2 confers resistance to PG9 and PG16
possibly by creating hindrance in antibody binding or masking crucial
residues of PG9 and PG16 epitopes. While extra PNGs downstream of
β-strand C region inhibits the antibody binding, the net positive
charge in β-strand C increases the interaction with PG9 and PG16.
The overall neutralization sensitivity of an Env is the outcome of char-
acteristic molecular features of the V2 loop and neutralization by
PG9/16 is balanced by the glycans, net positive charge and possibly
the length of the V2 loop. However, we do not rule out the possibility
that apart from V2 length and glycans in this region other determi-
nants elsewhere in the Env might also play a role in modulating
PG9 and PG16 sensitivity. Our ﬁnding indicates that if a vaccine
aims to elicit PG9 and PG16 like antibodies, the characteristics of
the V2 region should be taken into account towards optimum expo-
sure of their epitopes.Materials and methods
Mutagenesis
Site-directed mutagenesis was carried out by using tailor-made
primers to remove and/or introduce speciﬁc residue/s in a PCR reac-
tion using proof reading polymerase, Platinum Taq (Invitrogen Inc.).
DpnI digested puriﬁed PCR products were then annealed in presence
of pox DNA polymerase using Dry Down PCR Cloning kit (Clontech
Inc.) following manufacturer's protocol and as described previously
(Ringe et al., 2011).
Neutralization assay
The neutralization assay was carried out as described earlier
(Ringe et al., 2010, 2011). Brieﬂy, Env-pseudotyped viruses were in-
cubated with different concentrations of PG9 and PG16 MAbs for
1 h at 37°C, following which 1×104 TZM-bl cells were added into
the mixture in presence of 25 μg/ml DEAE dextran (Sigma Inc.). The
plates were incubated in a CO2 incubator for 48 h and the degree of
virus neutralization was assessed by measuring relative luminescence
units (RLU) in a luminometer (Victor 4, Perkin Elmer Inc.).
Cell-based binding assay
The relative interaction of Env with PG9 and PG16 MAbs were
assessed by cell-based binding assay as described elsewhere
(Doores and Burton, 2010; Wilen et al., 2011). Brieﬂy, 293 T cells
were transfected with equal amounts of Env plasmids and at 48 h
40 R. Ringe et al. / Virology 426 (2012) 34–41post-transfection, cells were washed to remove growth media follow-
ing which PG9 and PG16 MAbs were added at different concentra-
tions to allow binding with env+293 T cells for 1 h at 37°C and
subsequently with goat-anti-human IgG conjugated with horse rad-
ish peroxidase (HRP; Thermo Scientiﬁc, Inc.). The relative binding of
Env with PG9/PG16 MAbs were assessed by addition of luminol sub-
strate (Thermo Scientiﬁc, Inc) and measuring RLU in a luminometer.
Statistical analyses
The correlations were evaluated for statistical signiﬁcance by
Spearman test. Correlation co-efﬁcient expressed as Spearman's rho
(r) and P values shown at the top of each box were obtained by
using Graph Pad prism software. The median neutralization sensitivity
of Envs to PG9 and PG16 MAbs were calculated by using Wilcoxon
signed rank test and P values were obtained between different groups.
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